02877 SHINEWAY PHARM
- 9.300
- +0.161+1.76%
SHINEWAY PHARM News
神威藥業：年度報告 2023
Is Now The Time To Put China Shineway Pharmaceutical Group (HKG:2877) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the
SHINEWAY PHARM To Go Ex-Dividend On April 29th, 2024 With 0.461 HKD Dividend Per Share
March 30th - $SHINEWAY PHARM(02877.HK)$ is trading ex-dividend on April 29th, 2024. Shareholders of record on April 30th, 2024 will receive 0.461 HKD dividend per share on May 17th, 2024. The ex-d
China Shineway Pharmaceutical Group Grows 2023 Profit, Declares Interim 2024 Dividend
China Shineway Pharmaceutical Group (HKG:2877) posted a 2023 profit of 969.5 million yuan, or 1.28 yuan per share, up from 722.8 million yuan, or 0.96 yuan per share, a year earlier. The pharmaceutica
Shenwei Pharmaceutical (02877.HK)'s profit of RMB 969.5 million increased 34.1% year-on-year in 2023
Gelonghui, March 28, 丨 Shenwei Pharmaceutical (02877.HK) announced that for the year ended December 31, 2023, turnover was RMB 4,516 million, up 14.3% from last year; annual profit was RMB 969.5 million, up 34.1% from last year; earnings per share was RMB 128 points; declared the first interim dividend in 2024 of RMB 43 points per share; net assets of RMB 8.51 per share (equivalent to HK$9.36); and net cash per share of RMB 6.76 (equivalent to HK$7.43). In 2023, with the normalization of centralized procurement and
Shenwei Pharmaceutical (02877) will pay an interim dividend of HK$0.461 per share on May 17
Shenwei Pharmaceutical (02877) announced that it intends to pay an interim dividend of HK$0.461 per share on May 17, 2024...
SHINEWAY PHARM: 2023 ANNUAL RESULTS ANNOUNCEMENT AND DECLARATION OF 2024 FIRST INTERIM DIVIDEND
Shenwei Pharmaceutical (02877.HK) plans to hold a board meeting on March 28 to approve the annual results
Glonghui, March 18, 丨 Shenwei Pharmaceutical (02877.HK) announced that the company will hold a board meeting on Thursday, March 28, 2024 at Room 3109, 31/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong to (among others) approve the release of the company and its subsidiaries for the year ended 31 December 2023 and consider declaring dividends.
SHINEWAY PHARM: Notice of Board Meeting
China Shineway Pharmaceutical Group Limited's (HKG:2877) 30% Share Price Surge Not Quite Adding Up
China Shineway Pharmaceutical Group Limited (HKG:2877) shares have continued their recent momentum with a 30% gain in the last month alone. Looking back a bit further, it's encouraging to see the s
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose more than 5% to a new high, net profit pre-increased by more than 30% last year
Shenwei Pharmaceutical (02877) rose by more than 5%, reaching a new high of HK$10.1 since July 2018. As of press release, it rose 5.44% to HK$10.08, with a turnover of HK$29.741,900.
China Shineway Pharmaceutical Group Limited's (HKG:2877) Most Bullish Insider Is Top Key Executive Zhenjiang Li, and Their Holdings Value Went up by 8.8% Last Week
Key Insights Significant insider control over China Shineway Pharmaceutical Group implies vested interests in company growth The largest shareholder of the company is Zhenjiang Li with a 72% stake
China Shineway Pharmaceutical to Log Higher Profit in 2023; Shares Up 3%
China Shineway Pharmaceutical Group (HKG:2877) expects a 30% to 36% increase in its profit attributable to the owners for the year ended Dec. 31, 2023, compared with the 722.8 million yuan profit a ye
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose more than 6% after earnings, and net profit is expected to increase by about 30% to 36% year-on-year last year
Shenwei Pharmaceutical (02877) rose more than 6% after earnings. As of press release, it rose 6.04% to HK$9.3, with a turnover of HK$2,505,900.
Selected GLONGHUI Announcements (Hong Kong Stock) | Site B Releases 2023 Q4 and Annual Financial Report: Gross Margin Increased for Six Consecutive Quarters, Achieving Positive Operating Cash Flow Throughout the Year
[Today's Focus] Station B released its financial report for Q4 and the full year of 2023: gross margin increased for six consecutive quarters, achieving positive operating cash flow for the whole year on March 7, Beijing time (March 7, EST). Bilibili (NASDAQ: BILI, HKEX: 9626; hereinafter referred to as “Station B”) announced unaudited financial reports for the fourth quarter and full year ending December 31, 2023. Financial reports show that in 2023, Station B's total revenue for the full year reached RMB 22.53 billion, of which total revenue for the fourth quarter reached RMB 6.35 billion. In 2023, B stands to ensure high-quality user growth
China Shineway Pharmaceutical Group Expects 30%-36% Increase in 2023 Profit
China Shineway Pharmaceutical Group Expects 30%-36% Increase in 2023 Profit
Shenwei Pharmaceutical (02877) is pleased. The profit attributable to shareholders is expected to increase by about 30% to 36% year-on-year
Shenwei Pharmaceutical (02877) announced that the profit attributable to the company's owners for the year ended December 31, 2023 is expected to increase by about 30% to 36% compared to the same period last year (2022: about RMB 723 million).
SHINEWAY PHARM: POSITIVE PROFIT ALERT
Is China Shineway Pharmaceutical Group Limited's (HKG:2877) Recent Stock Performance Tethered To Its Strong Fundamentals?
Most readers would already be aware that China Shineway Pharmaceutical Group's (HKG:2877) stock increased significantly by 27% over the past three months. Given the company's impressive performance,
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose nearly 7% to a new high and was included in 5 indices including the Hang Seng Composite Index
The Zhitong Finance App learned that Shenwei Pharmaceutical (02877) rose by nearly 7%, reaching a high of HK$8.97 since August 2023. As of press release, it rose 6.7% to HK$8.92, with a turnover of HK$4.923 million. According to the news, Hang Seng Index Limited recently announced the results of the Hang Seng Index series quarterly review for the year ended 31 December 2023. Among them, Shenwei Pharmaceutical has been included in a total of 5 indices, including the Hang Seng Composite Index, etc. The relevant changes will take effect on March 4, 2024. CCB International previously stated that benefiting from the general increase in medical product sales in FY2023, the company
Analysis
Price Target
No Data
